AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27031473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 27031473 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (n=4, ≥60 years)
Number of subjects: 18
Study 27031473 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=4, ≥60 years)
Number of subjects: 18
Study 24980238 — intervention group
Group type: EXPERIMENTAL
Intervention: Cauterization of both distal and proximal nerve stumps (Group 1)
Number of subjects: 80
Study 24980238 — intervention group
Group type: COMPARATOR
Intervention: Cauterization of only the proximal nerve stump (Group 2)
Number of subjects: 80
Study 23756400 — intervention group
Group type: EXPERIMENTAL
Intervention: Shiitake mushroom extract (700 mg, two times per day)
Number of subjects: 0
Study 23756400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20653494 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine orodispersible tablet (ODT)
Number of subjects: 175
Study 20653494 — intervention group
Group type: COMPARATOR
Intervention: Oral conventional tablet (OCT)
Number of subjects: 175
Study 18408938 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine 1 mg/kg (Group I, n = 60)
Number of subjects: 110
Study 18408938 — intervention group
Group type: COMPARATOR
Intervention: Tramadol 2 mg/kg (Group II, n = 50)
Number of subjects: 110
Study 17153649 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.12%
Number of subjects: 0
Study 17153649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14555299 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg twice daily
Number of subjects: 27
Study 14555299 — intervention group
Group type: COMPARATOR
Intervention: Sodium cromoglycate (SCG) 2 mg four times daily
Number of subjects: 27
Study 11009131 — intervention group
Group type: EXPERIMENTAL
Intervention: Church-based health education program for mammography promotion
Number of subjects: 1967
Study 11009131 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based strategies for recruitment
Number of subjects: 1967
Study 9361692 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 25
Study 9361692 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 25
Study 9361692 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 25
Study 9361692 — intervention group
Group type: COMPARATOR
Intervention: Healthy Control
Number of subjects: 25
Study 9361692 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive NIDDM
Number of subjects: 25
Study 1557840 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-dose heparin
Number of subjects: 68
Study 3552466 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous high-frequency jet ventilation (HFJV)
Number of subjects: 9
Study 3552466 — intervention group
Group type: COMPARATOR
Intervention: Intermittent positive-pressure breathing (IPPB)
Number of subjects: 9
Study 3552466 — intervention group
Group type: COMPARATOR
Intervention: Asynchronous high-frequency jet ventilation (HFJV)
Number of subjects: 9
Study 29889755 — intervention group
Group type: EXPERIMENTAL
Intervention: Salpingectomy
Number of subjects: 44
Study 29889755 — intervention group
Group type: COMPARATOR
Intervention: Standard Tubal Ligation
Number of subjects: 44
Study 27821789 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver sulfadiazine (SSD)-impregnated hydrocolloid dressing
Number of subjects: 14
Study 27821789 — intervention group
Group type: COMPARATOR
Intervention: Hydrocolloid dressing
Number of subjects: 14
Study 24856872 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol, 25,000IU, per week orally for 13 weeks
Number of subjects: 55
Study 24856872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 23357807 — intervention group
Group type: EXPERIMENTAL
Intervention: NAL-NL2
Number of subjects: 14
Study 23357807 — intervention group
Group type: EXPERIMENTAL
Intervention: CAM2
Number of subjects: 14
Study 23357807 — intervention group
Group type: COMPARATOR
Intervention: NAL-NL2 and CAM2
Number of subjects: 14
Study 20963833 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high frequency percussive ventilation (NHFPV)
Number of subjects: 46
Study 20963833 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 46
Study 19549432 — intervention group
Group type: EXPERIMENTAL
Intervention: CIC80 b.i.d.
Number of subjects: 711
Study 19549432 — intervention group
Group type: EXPERIMENTAL
Intervention: CIC160 q.d.
Number of subjects: 711
Study 19549432 — intervention group
Group type: EXPERIMENTAL
Intervention: CIC80 b.i.d./CIC160 q.d.
Number of subjects: 711
Study 19549432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 711
Study 19549432 — intervention group
Group type: EXPERIMENTAL
Intervention: CIC treatments (all groups)
Number of subjects: 711
Study 19549432 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 711
Study 16401531 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and Support Programme (TSP) - 8 weekly sessions, 1 hour each, teaching massage skills
Number of subjects: 95
Study 16401531 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list Control Group
Number of subjects: 95
Study 15253580 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 61
Study 15253580 — intervention group
Group type: COMPARATOR
Intervention: Control (Conventional treatment)
Number of subjects: 61
Study 11568516 — intervention group
Group type: EXPERIMENTAL
Intervention: High lactose formula (HLF)
Number of subjects: 99
Study 11568516 — intervention group
Group type: COMPARATOR
Intervention: Low lactose formula (LLF)
Number of subjects: 99
Study 11568516 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk (more than 10%)
Number of subjects: 99
Study 11568516 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk (less than 10%)
Number of subjects: 99
Study 9709275 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-view mammography screening
Number of subjects: 14842
Study 9709275 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 14842
Study 8104272 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular inhaled salbutamol (200 micrograms four times daily for 2 weeks)
Number of subjects: 13
Study 8104272 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 weeks)
Number of subjects: 13
Study 3769482 — intervention group
Group type: EXPERIMENTAL
Intervention: DHPA 150 mg + E2‐EN 10 mg (group I, n = 9)
Number of subjects: 16
Study 3769482 — intervention group
Group type: COMPARATOR
Intervention: Half-dose of DHPA + E2‐EN (group II, n = 7)
Number of subjects: 16
Study 3769482 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (group I and group II)
Number of subjects: 16
Study 29268031 — intervention group
Group type: EXPERIMENTAL
Intervention: 30:240 (n = 11; 4‐6 × 30‐s bouts, 4 min rest)
Number of subjects: 43
Study 29268031 — intervention group
Group type: EXPERIMENTAL
Intervention: 15:120 (n = 11; 8‐12 × 15‐s bouts, 2 min rest)
Number of subjects: 43
Study 29268031 — intervention group
Group type: EXPERIMENTAL
Intervention: 5:40 (n = 12; 24‐36 × 5‐s bouts, 40 s rest)
Number of subjects: 43
Study 29268031 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising control (n = 9)
Number of subjects: 43
Study 27297013 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine iron prophylaxis (60 mg ferrous sulfate plus 400 μg folic acid daily)
Number of subjects: 4326
Study 27297013 — intervention group
Group type: COMPARATOR
Intervention: Selective iron prophylaxis (1 mg folic acid daily and Hb screening with treatment for low Hb)
Number of subjects: 4326
Study 24980710 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended therapy (72 weeks of PEG‐IFNα‐2a)
Number of subjects: 80
Study 24980710 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (48 weeks of PEG‐IFNα‐2a)
Number of subjects: 80
Study 22476362 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based education (experiment)
Number of subjects: 147
Study 22476362 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face education with a nurse (control)
Number of subjects: 147
Study 22476362 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (experiment and control)
Number of subjects: 147
Study 22476362 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic variables
Number of subjects: 147
Study 20535662 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration + static stretch group (V)
Number of subjects: 34
Study 20535662 — intervention group
Group type: COMPARATOR
Intervention: Static stretch group (SS)
Number of subjects: 34
Study 18533777 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated subgingival scaling (test)
Number of subjects: 26
Study 18533777 — intervention group
Group type: COMPARATOR
Intervention: Periodontal surgery (control)
Number of subjects: 26
Study 15948808 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day sequential therapy (rabeprazole 20 mg b.d. plus amoxicillin 1 g b.d. for the first 5 days, followed by rabeprazole 20 mg, clarithromycin 500 mg and tinidazole 500 mg, all b.d., for the remaining 5 days)
Number of subjects: 179
Study 15948808 — intervention group
Group type: COMPARATOR
Intervention: Standard 7-day triple regimen (rabeprazole 20 mg, clarithromycin 500 mg and amoxicillin 1 g, all b.d.)
Number of subjects: 179
Study 12783043 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (53% fat)
Number of subjects: 11
Study 12783043 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (17% fat)
Number of subjects: 11
Study 10482981 — intervention group
Group type: EXPERIMENTAL
Intervention: t(12;21) positive acute lymphoblastic leukemia
Number of subjects: 169
Study 9772599 — intervention group
Group type: EXPERIMENTAL
Intervention: Wenyang Tongluo Mixture (WYTLM)
Number of subjects: 68
Study 9772599 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol orally and beclomethasone dipropionate aerosol
Number of subjects: 68
Study 1929610 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative tune-up using pulmonary artery catheter (PA catheter)
Number of subjects: 89
Study 1929610 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preoperative tune-up)
Number of subjects: 89
Study 6615689 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol 400 mg
Number of subjects: 24
Study 6615689 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol 200 mg
Number of subjects: 24
Study 6615689 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine 50 mg
Number of subjects: 24
Study 6615689 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine 100 mg
Number of subjects: 24
Study 6615689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30081658 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary sodium nitrite during primary PCI
Number of subjects: 0
Study 30081658 — intervention group
Group type: COMPARATOR
Intervention: Standard primary PCI only (placebo)
Number of subjects: 0
Study 26768003 — intervention group
Group type: EXPERIMENTAL
Intervention: E-learning course in physiotherapy in oncology (PHO)
Number of subjects: 67
Study 26768003 — intervention group
Group type: COMPARATOR
Intervention: Traditional classroom course in physiotherapy in oncology (PHO)
Number of subjects: 67
Study 26681132 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa flavanol (CF) ingestion (900 mg CF per study day)
Number of subjects: 57
Study 26681132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 24716412 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment + rhBNP (recombinant human B-type natriuretic peptide) for up to 7 days
Number of subjects: 0
Study 24716412 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 0
Study 24716412 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBNP group
Number of subjects: 0
Study 21965520 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptive rehabilitation (10 sessions in one month)
Number of subjects: 75
Study 21965520 — intervention group
Group type: EXPERIMENTAL
Intervention: Back School programme
Number of subjects: 75
Study 21965520 — intervention group
Group type: COMPARATOR
Intervention: Control group (medical and pharmacological assistance)
Number of subjects: 75
Study 19237881 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemofiltration (25 mL/kg/hr) for a 96-hour period
Number of subjects: 80
Study 19237881 — intervention group
Group type: COMPARATOR
Intervention: Conventional management (Control group)
Number of subjects: 80
Study 17228672 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative X-ray imaging (Group I)
Number of subjects: 141
Study 17228672 — intervention group
Group type: COMPARATOR
Intervention: Standard THA method (Group S)
Number of subjects: 141
Study 15689054 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel polyherbal formulation (PF; Aller‐7/NR‐A2)
Number of subjects: 545
Study 15689054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 545
Study 11705489 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib at a dose of 500 mg twice daily
Number of subjects: 40
Study 11705489 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib at a dose of 400 mg twice daily
Number of subjects: 40
Study 11705489 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (various doses)
Number of subjects: 40
Study 11705489 — intervention group
Group type: EXPERIMENTAL
Intervention: PET scan responses
Number of subjects: 40
Study 9279340 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 0
Study 9279340 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study 7993413 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dobutamine (5 to 200 micrograms per kilogram of body weight per minute)
Number of subjects: 109
Study 7993413 — intervention group
Group type: COMPARATOR
Intervention: Control group (dobutamine administered only if cardiac index was below 2.8 liters per minute per square meter)
Number of subjects: 109
Study 3281701 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.6 mg by mouth 2 h before operation
Number of subjects: 20
Study 3281701 — intervention group
Group type: COMPARATOR
Intervention: Control group (no clonidine)
Number of subjects: 20
Study 29453232 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA) 1,000 mg by mouth twice daily for 12 weeks
Number of subjects: 64
Study 29453232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 29141061 — intervention group
Group type: EXPERIMENTAL
Intervention: HQ-free system
Number of subjects: 30
Study 29141061 — intervention group
Group type: COMPARATOR
Intervention: HQ-based system
Number of subjects: 30
Study 29141061 — intervention group
Group type: EXPERIMENTAL
Intervention: Both systems
Number of subjects: 30
Study 26315284 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Management of Infectious Disease (IMID) training
Number of subjects: 36
Study 26315284 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site support (OSS)
Number of subjects: 36
Study 26315284 — intervention group
Group type: COMPARATOR
Intervention: Control group (no OSS)
Number of subjects: 36
Study 23833564 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (10 mg/kg IV every 3 weeks for up to 4 doses)
Number of subjects: 59
Study 23833564 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacarbazine (850 mg/m2 IV every 3 weeks)
Number of subjects: 59
Study 23833564 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin/paclitaxel (Paclitaxel 175 mg/m2 IV and Carboplatin [AUC=6] IV every 3 weeks)
Number of subjects: 59
Study 23833564 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab maintenance (10 mg/kg every 12 weeks)
Number of subjects: 59
Study 23833564 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab with Dacarbazine
Number of subjects: 59
Study 23833564 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab with Carboplatin/Paclitaxel
Number of subjects: 59
Study 21545273 — intervention group
Group type: EXPERIMENTAL
Intervention: Pumpkin seed oil (n = 21)
Number of subjects: 35
Study 21545273 — intervention group
Group type: COMPARATOR
Intervention: Wheat germ oil (placebo; n = 14)
Number of subjects: 35
Study 18438267 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine 1:100,000 and lidocaine 1%
Number of subjects: 22
Study 18438267 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 22
Study 15374698 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary FSH
Number of subjects: 67
Study 15374698 — intervention group
Group type: COMPARATOR
Intervention: Recombinant FSH
Number of subjects: 67
Study 11583471 — intervention group
Group type: EXPERIMENTAL
Intervention: ketoconazole (three 200 mg doses spaced 12 hours apart)
Number of subjects: 8
Study 11583471 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no ketoconazole)
Number of subjects: 8
Study 9630408 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir
Number of subjects: 511
Study 9630408 — intervention group
Group type: EXPERIMENTAL
Intervention: Netivudine
Number of subjects: 511
Study 8015061 — intervention group
Group type: EXPERIMENTAL
Intervention: ESWL in situ
Number of subjects: 70
Study 8015061 — intervention group
Group type: COMPARATOR
Intervention: Pre-ESWL stone manipulation
Number of subjects: 70
Study 2643751 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate alone
Number of subjects: 21
Study 2643751 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate and cholestyramine combined
Number of subjects: 21
Study 2643751 — intervention group
Group type: COMPARATOR
Intervention: Cholestyramine
Number of subjects: 21
Study 1099860 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg diazepam intravenously as preoperative sedative
Number of subjects: 136
Study 1099860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 30755274 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold micropulse laser
Number of subjects: 0
Study 30755274 — intervention group
Group type: COMPARATOR
Intervention: Standard threshold laser
Number of subjects: 0
Study 28236077 — intervention group
Group type: EXPERIMENTAL
Intervention: TeleCARE (remote, tailored‐risk communication intervention)
Number of subjects: 481
Study 28236077 — intervention group
Group type: COMPARATOR
Intervention: Mailed educational brochure intervention
Number of subjects: 481
Study 25929392 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein Diet (PD)
Number of subjects: 32
Study 23760281 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictable scaling of ID (decreasing from high 6.5 to low 2.5)
Number of subjects: 0
Study 23760281 — intervention group
Group type: COMPARATOR
Intervention: Random ID presentation
Number of subjects: 0
Study 23760281 — intervention group
Group type: COMPARATOR
Intervention: Constant ID presentation
Number of subjects: 0
Study 21537559 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine children
Number of subjects: 30
Study 21537559 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 19309327 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster care intervention
Number of subjects: 0
Study 19309327 — intervention group
Group type: COMPARATOR
Intervention: Institutional care
Number of subjects: 0
Study 19309327 — intervention group
Group type: COMPARATOR
Intervention: Community sample
Number of subjects: 0
Study 16782099 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 53
Study 16782099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 16782099 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative MR imaging
Number of subjects: 53
Study 15175486 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal descriptors (e.g., 'common' for constipation, 'rare' for pancreatitis)
Number of subjects: 120
Study 15175486 — intervention group
Group type: COMPARATOR
Intervention: Numerical descriptors (e.g., 2.5% for constipation, 0.04% for pancreatitis)
Number of subjects: 120
Study 11672493 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamphetamine (up to 60 mg daily)
Number of subjects: 41
Study 11672493 — intervention group
Group type: COMPARATOR
Intervention: Counselling (weekly)
Number of subjects: 41
Study 9234826 — intervention group
Group type: EXPERIMENTAL
Intervention: 50-min treadmill walk at 50% VO2max
Number of subjects: 61
Study 9234826 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise control day
Number of subjects: 61
Study 8306143 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittently closed drainage systems
Number of subjects: 40
Study 8306143 — intervention group
Group type: COMPARATOR
Intervention: Permanently closed drainage systems
Number of subjects: 40
Study 3450328 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory resistive training (IRT) with a P Flex device
Number of subjects: 20
Study 3450328 — intervention group
Group type: COMPARATOR
Intervention: Conventional breathing retraining (BR)
Number of subjects: 20
Study 30318837 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (0.3 g·kg‐1 body mass)
Number of subjects: 8
Study 30318837 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin, 0.2 g·kg‐1 body mass)
Number of subjects: 8
Study 26135690 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatogastrostomy (PG)
Number of subjects: 440
Study 26135690 — intervention group
Group type: COMPARATOR
Intervention: Pancreatojejunostomy (PJ)
Number of subjects: 440
Study 24196543 — intervention group
Group type: EXPERIMENTAL
Intervention: Minilaparotomy (MC)
Number of subjects: 48
Study 24196543 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 48
Study 22125197 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold polypectomy for <10-mm polyps
Number of subjects: 823
Study 19896801 — intervention group
Group type: EXPERIMENTAL
Intervention: hylan G-F 20
Number of subjects: 0
Study 19896801 — intervention group
Group type: COMPARATOR
Intervention: appropriate care
Number of subjects: 0
Study 18303254 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin (75 mg/day plus 75-162 mg/day)
Number of subjects: 593
Study 18303254 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 593